Ondine Biomedical Inc

Ondine Biomedical Inc has a capital structure with 519,551,468 basic and diluted shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which limits the ability to evaluate its short-term financial flexibility.

The company reported a loss per share of -0.07 CAD and revenue of 2,049,000 CAD in the latest period, suggesting a lack of profitability and a very small revenue base. These figures fall significantly below the industry median for profitability and revenue scale, indicating a weak competitive position in the Medical Equipment, Supplies & Distribution industry.

Ondine Biomedical Inc's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risk. The absence of segment data limits the ability to evaluate exposure to regional economic shifts or product-specific demand fluctuations.

The company's growth trajectory is unclear, as no forward-looking revenue or earnings guidance is provided in the available data. The lack of historical revenue growth data and the absence of analyst estimates for future periods suggest limited visibility into the company's ability to scale operations or improve profitability.

The risk assessment highlights a low dilution potential, but the lack of liquidity data and the absence of a clear path to profitability raise concerns about the company's long-term viability. The absence of balance-sheet inputs and the lack of going-concern language in source documents further complicate the evaluation of financial risk.

Recent filings and transcripts do not provide additional insight into the company's strategic direction or operational performance. The absence of detailed disclosures in 10-K or 10-Q filings, as well as the lack of investor call transcripts, limits the ability to assess management's execution and response to market challenges.

Revenue C$2.0M, +70,3% YoY; Operating income −31,3% YoY.

• ▍Revenue C$2.0M, +70,3% YoY
• ▍Operating income −31,3% YoY
• ▍Net income −32,5% YoY
• ▍Free cash flow −32,4% YoY
• ▍Net margin -932.1%

Revenue C$1.2M, +88,6% YoY; Operating income +26,3% YoY.

• ▍Revenue C$1.2M, +88,6% YoY
• ▍Operating income +26,3% YoY
• ▍Net income +25,6% YoY
• ▍Free cash flow +27,0% YoY
• ▍Net margin -1198.0%

Revenue C$638.0k, −75,2% YoY; Operating income +59,1% YoY.

• ▍Revenue C$638.0k, −75,2% YoY
• ▍Operating income +59,1% YoY
• ▍Net income +61,3% YoY
• ▍Free cash flow +61,4% YoY
• ▍Net margin -3036.4%